期刊
CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY
卷 11, 期 5, 页码 1405-1436出版社
ELSEVIER INC
DOI: 10.1016/j.jcmgh.2021.01.008
关键词
Antimetastatic Therapy; Cancer-Associated Fibroblasts; Pancreatic Adenocarcinoma; Stromal Cell Cross-Talk; Stroma Normalization; Macrophages; Somatostatin Receptor
资金
- Ligue Nationale Contre le Cancer
- Labex Toucan
- French Institut National du Cancer INCa [PLBIO15-115, PAIR18-080, PAIR18-082]
- Association pour la Recherche sur le Cancer ARC [20191209786]
- Plan Cancer 3R
- Fondation pour la Recherche Medicale [FRM 40493]
The study suggests that SOM230 has the potential to be an effective anti-metastatic therapy in PDA by regulating stromal activities, reducing inflammatory responses, and improving the immunosuppressive tumor microenvironment. This pharmacotherapy shows promise in reshaping the tumor environment and enhancing treatment outcomes for pancreatic cancer patients.
BACKGROUND & AIMS: Cancer-associated fibroblasts (CAFs) from pancreatic adenocarcinoma (PDA) present high protein synthesis rates. CAFs express the G-protein-coupled somatostatin receptor sst1. The sst1 agonist SOM230 blocks CAF protumoral features in vitro and in immunocompromised mice. We have explored here the therapeutic potential of SOM230, and underlying mechanisms, in immunocompetent models of murine PDA mimicking the heavy fibrotic and immunosuppressive stroma observed in patient tumors. METHODS: Large-scale mass spectrometry analyses were performed on media conditioned from 9 patient PDA-derived CAF primary cultures. Spontaneous transgenic and experimental (orthotopic co-graft of tumor cells plus CAFs) PDA-bearing mice were longitudinally ultrasound-monitored for tumor and metastatic progression. Histopathology and flow cytometry analyses were performed on primary tumors and metastases. Stromal signatures were functionally validated through bioinformatics using several published, and 1 original, PDA database. RESULTS: Proteomics on the CAF secretome showed that SOM230 controls stromal activities including inflammatory responses. Among the identified secreted proteins, we validated that colony-stimulating factor 1 (CSF-1) (a macrophage growth factor) was reduced by SOM230 in the tumor and plasma of PDA-harboring mice, alongside intratumor stromal normalization (reduced CAF and macrophage activities), and dramatic metastasis reduction. In transgenic mice, these SOM230 benefits alleviate the chemotherapy-induced (gemcitabine) immunosuppressive stroma reshaping. Mechanistically, SOM230 acts in vivo on CAFs through sst1 to disrupt prometastatic CAF production of CSF-1 and cross-talk with macrophages. We found that in patients, stromal CSF-1 was associated with aggressive PDA forms. CONCLUSIONS: We propose SOM230 as an antimetastatic therapy in PDA for its capacity to remodel the fibrotic and immunosuppressive myeloid stroma. This pharmacotherapy should benefit PDA patients treated with chemotherapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据